Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in the ...
Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product has won approval from the European Commission to treat children aged 6-11 suffering from severe atopic dermatitis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback